(Total Views: 678)
Posted On: 04/27/2025 1:54:02 AM
Post# of 154678
I'm prefacing this by saying that I know we all hate him, but...I saw this headline on an article before I saw who it was from, then I looked and didn't know how to feel, but while I know he's not a fan of Cytodyn, the title of the article he wrote got me pumped for us...
The title from Adam F*********:
Biotech is back, baby! It’s all upside from here
Plus: The ‘new’ FDA wants to approve a lot of drugs
With our safety profile, if he's right about the current FDA we could be looking at a much sooner approval than we thought. My honest opinion was a partnership this year in some indication, the CRC trial starting, and some initial data on Alzheimer's and/or pulmonary fibrosis, with approval coming for something in the next 1-3 years hopefully. With this new mTNBC data we're set to unveil, and our safety manuscript about to be published, I can potentially see approval with this FDA on an abbreviated timeline.
The title from Adam F*********:
Biotech is back, baby! It’s all upside from here
Plus: The ‘new’ FDA wants to approve a lot of drugs
With our safety profile, if he's right about the current FDA we could be looking at a much sooner approval than we thought. My honest opinion was a partnership this year in some indication, the CRC trial starting, and some initial data on Alzheimer's and/or pulmonary fibrosis, with approval coming for something in the next 1-3 years hopefully. With this new mTNBC data we're set to unveil, and our safety manuscript about to be published, I can potentially see approval with this FDA on an abbreviated timeline.
(13)
(0)
